Pfizer 2012 Annual Report Download - page 116

Download and view the complete annual report

Please find page 116 of the 2012 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 121

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
2012 Financial Report
115
Significant Product Revenues
The following table provides revenues by product:
Year Ended December 31,
(MILLIONS OF DOLLARS) 2012 2011(a) 2010
Revenues from biopharmaceutical products:
Lyrica $ 4,158 $ 3,693 $ 3,063
Lipitor(b) 3,948 9,577 10,733
Enbrel (Outside the U.S. and Canada) 3,737 3,666 3,274
Prevnar 13/Prevenar 13 3,718 3,657 2,416
Celebrex 2,719 2,523 2,374
Viagra 2,051 1,981 1,928
Norvasc 1,349 1,445 1,506
Zyvox 1,345 1,283 1,176
Sutent 1,236 1,187 1,066
Premarin family 1,073 1,013 1,040
Genotropin 832 889 885
Xalatan/Xalacom 806 1,250 1,749
BeneFIX 775 693 643
Detrol/Detrol LA 761 883 1,013
Vfend 754 747 825
Chantix/Champix 670 720 755
Pristiq 630 577 466
ReFacto AF/Xyntha 584 506 404
Zoloft 541 573 532
Revatio 534 535 481
Medrol 523 510 455
Zosyn/Tazocin 484 636 952
Zithromax/Zmax 435 453 415
Effexor 425 678 1,718
Prevnar/Prevenar (7-valent) 399 488 1,253
Fragmin 381 382 341
Relpax 368 341 323
Rapamune 346 372 388
Cardura 338 380 413
Tygacil 335 298 324
Aricept(c) 326 450 454
Xanax XR 274 306 307
BMP2 263 340 400
Sulperazon 262 218 213
Diflucan 259 265 278
Caduet 258 538 527
Neurontin 235 289 322
Dalacin/Cleocin 232 192 214
Unasyn 228 231 244
Metaxalone/Skelaxin(d) 223 203 —
Inspra 214 195 157
Toviaz 207 187 137
Somavert 197 183 157
Alliance revenues(e) 3,492 3,630 4,084
All other biopharmaceutical products(f) 8,289 8,584 8,118
Total revenues from biopharmaceutical products 51,214 57,747 58,523
Revenues from other products:
Animal Health 4,299 4,184 3,575
Consumer Healthcare 3,212 3,028 2,748
Other(g) 261 300 319
Revenues $ 58,986 $ 65,259 $ 65,165
(a) For 2011, includes King commencing on the acquisition date of January 31, 2011.